The fibroblast surface markers FAP, anti‐fibroblast, and FSP are expressed by cells of epithelial origin and may be altered during epithelial‐to‐mesenchymal transition
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The identification of fibroblasts and cancer‐associated fibroblasts from human cancer tissue using surface markers is difficult, especially because the markers used currently are usually not expressed solely by fibroblasts, and the identification of fibroblast‐specific surface molecules is still under investigation. It was aimed to compare three commercially available antibodies in the detection of different surface epitopes of fibroblasts (anti‐fibroblast, fibroblast activation protein α, and fibroblast surface protein). The specificity of their expression, employing fibroblast cell lines and tumor‐derived fibroblasts from breast and prostate tissues was investigated. Both the established fibroblast cell line HFF‐1 and ex vivo primary fibroblasts isolated from breast and prostate cancer tissues expressed the tested surface markers to different degrees. Surprisingly, those markers were expressed also by permanent cell lines of epithelial origin, both benign and cancer‐derived (breast‐cell lines MCF 10A, HMLE and prostate‐cell lines BPH‐1, DU 145, and PC‐3). The expression of fibroblast activation protein α increased on the surface of previously described models of epithelial cells undergoing epithelial‐to‐mesenchymal transition in response to treatment with TGF‐β1. To prove the co‐expression of the fibroblast markers on cells of epithelial origin, we used freshly dissociated human prostate and breast cancer tissues. The results confirmed the co‐expression of anti‐fibroblast and fibroblast surface protein on CD31/CD45‐negative/EpCAM‐positive epithelial cells. In summary, our data support the findings that the tested fibroblast markers are not fibroblast specific and may be expressed also by cells of epithelial origin (e.g., cells undergoing EMT). Therefore, the expression of these markers should be interpreted with caution, and the combination of several epitopes for both positive (anti‐fibroblast or fibroblast activation protein α) and negative (EpCAM) identification of fibroblasts from breast and prostate tumor tissues is advised. © 2017 International Society for Advancement of Cytometry
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells
Mishra, P. J., Mishra, P. J., Humeniuk, R., Medina, D. J., Alexe, G., Mesirov, J. P., Ganesan, S., Glod, J. W., & Banerjee, D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0943 · Cited by 912 · cited 1×
“FSP antibody was used to characterize myofibroblasts differentiated from human mesenchymal stem cells (7) and in com-”
MethodHuman breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells
Elenbaas, B., Spirio, L., Koerner, F., Fleming, M. D., Zimonjic, D. B., Donaher, J. L., Popescu, N. C., Hahn, W. C., & Weinberg, R. A. (2001) · Genes & Development · doi:10.1101/gad.828901 · Cited by 878 · cited 1×
“Weinberg, Whitehead Institute, Cambridge, MA, USA and cultivated as described previously (15,16).”
BackgroundCancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth
Shiga, K., Hara, M., Nagasaki, T., Sato, T., Takahashi, H., & Takeyama, H. (2015) · Cancers · doi:10.3390/cancers7040902 · Cited by 774
ROCK Inhibitor and Feeder Cells Induce the Conditional Reprogramming of Epithelial Cells
Liu, X., Ory, V., Chapman, S., Yuan, H., Albanese, C., Kallakury, B., Timofeeva, O. A., Nealon, C., Dakic, A., Simic, V., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.10.036 · Cited by 726
Giannoni, E., Bianchini, F., Masieri, L., Serni, S., Torre, E., Calorini, L., & Chiarugi, P. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0785 · Cited by 596
Cited by
In search of definitions: Cancer‐associated fibroblasts and their markers
Nurmik, M., Ullmann, P., Rodriguez, F., Haan, S., & Letellier, E. (2020) · International Journal of Cancer · doi:10.1002/ijc.32193 · Cited by 739
The role of fibroblast activation protein in health and malignancy
Fitzgerald, A. A., & Weiner, L. M. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09909-3 · Cited by 589
Cancer-associated fibroblasts: from basic science to anticancer therapy
Yang, D., Liu, J., Qian, H., & Zhuang, Q. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01013-0 · Cited by 572
Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics
Puré, E., & Blomberg, R. (2018) · Oncogene · doi:10.1038/s41388-018-0275-3 · Cited by 391
Xin, L., Gao, J., Zheng, Z., Chen, Y., Lv, S., Zhao, Z., Yu, C., Yang, X., & Zhang, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.648187 · Cited by 203
Galland, S., & Stamenkovic, I. (2020) · The Journal of Pathology · doi:10.1002/path.5357 · Cited by 165
Cherry, C., Andorko, J. I., Krishnan, K., Mejías, J. C., Nguyen, H. H., Stivers, K. B., Gray-Gaillard, E. F., Ruta, A., Han, J., Hamada, N., et al. (2023) · GeroScience · doi:10.1007/s11357-023-00785-7 · Cited by 66
Metadata
- Authors
- Kahounová, Z., Kurfürstová, D., Bouchal, J., Kharaishvili, G., Navrátil, J., Remšík, J., Šimečková, Š., Študent, V., Kozubík, A., & Souček, K.
- Venue
- Cytometry Part A
- Publisher
- Wiley
- Published
- 2017-04-06
- Volume
- 93
- Issue
- 9
- Pages
- 941-951
- ISSN
- 1552-4922 (ISSN-L)
- 1552-4930
- OpenAlex
- W2604739831
- Cited by
- 88
- References
- 5
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.